- Sales of $659 million grew 11% as reported and in constant
currency
- GAAP EPS of $2.60; non-GAAP EPS of $2.66, a 23% increase from
prior year
- Growth led by strong performance in pharmaceutical and
industrial end markets
- Double-digit growth in both instrument sales and recurring
revenues
- Balanced customer demand across the Americas, Europe and
Asia
Waters Corporation (NYSE: WAT) today announced third quarter
2021 sales of $659 million, an 11% increase as reported, compared
to sales of $594 million for the third quarter of 2020. Foreign
currency translation benefited sales growth by less than 1% for the
quarter.
On a GAAP basis, diluted earnings per share (EPS) for the third
quarter of 2021 increased to $2.60, compared to $2.03 for the third
quarter of 2020. On a non-GAAP basis, EPS increased to $2.66,
compared to $2.16 for the third quarter of 2020. A description and
reconciliation of GAAP to non-GAAP results appear in the tables
below and can be found on the Company’s website www.waters.com in
the Investor Relations section.
On a GAAP basis, net cash provided by operating activities was
$168 million for the third quarter of 2021, compared to $173
million for the third quarter of 2020. On a non-GAAP basis,
adjusted free cash flow for the third quarter of 2021 was $140
million versus $190 million for the third quarter of 2020.
For the first nine months of 2021, the Company’s sales were
$1,949 million, an increase of 23% as reported, compared to sales
of $1,579 million for the first nine months of 2020. Foreign
currency translation benefited sales growth by approximately 2% for
the first nine months of 2021.
On a GAAP basis, EPS for the first nine months of 2021 increased
to $7.66, compared to $4.86 for the first nine months of 2020. On a
non-GAAP basis, EPS increased to $7.54, compared to $5.41 in the
first nine months of 2020.
On a GAAP basis, net cash provided by operating activities was
$529 million for the first nine months of 2021, compared to $523
million for the first nine months of 2020. On a non-GAAP basis,
adjusted free cash flow for the first nine months of 2021 was $488
million versus $486 million for the first nine months of 2020.
“I would like to thank our colleagues globally for their
continued commitment and drive as we support our customers through
the pandemic,” said Dr. Udit Batra, President and Chief Executive
Officer of Waters Corporation. “We are very pleased with our third
quarter results led by strong growth in our pharmaceutical and
industrial end markets. We saw balanced double-digit growth in our
instruments and recurring revenue portfolios which gives us
confidence in the durability of our commercial momentum. We are
excited to partner with both Sartorius and the University of
Delaware, as we work to solve some of the complex problems facing
bioprocessing customers.”
Unless otherwise noted, sales growth and decline percentages are
presented on an as-reported basis and are the same as the sales
growth and decline percentages presented on a constant-currency
basis as compared with the same period in the prior year, each of
which is detailed in the reconciliation of sales growth rates to
constant-currency growth rates in the tables below.
During the third quarter of 2021, sales into the pharmaceutical
market increased 16%, sales into the industrial market increased 9%
and sales into the academic and government markets decreased 9% as
reported and 11% in constant currency. For the first nine months of
2021, sales into the pharmaceutical market increased 27% as
reported and 24% in constant currency, sales into the industrial
market increased 23% as reported and 19% in constant currency and
sales into the academic and government markets increased 8% as
reported and 6% in constant currency.
During the third quarter, recurring revenues, which represent
the combination of service and precision chemistries revenues,
increased 11%, while instrument system sales increased 10%. For the
first nine months of 2021, recurring revenues increased 18% as
reported and 15% in constant currency, while instrument system
sales increased 31% as reported and 29% in constant currency.
Geographically, sales in Asia during the quarter increased 8%,
sales in the Americas increased 16% (with U.S. sales growing 13%)
and sales in Europe increased 10% as reported and 8% in constant
currency. For the first nine months of 2021, sales in Asia
increased 25% as reported and 24% in constant currency, sales in
the Americas increased 20% as reported and 19% in constant currency
(with U.S. sales growing 17%) and sales in Europe increased 26% as
reported and 19% in constant currency.
Fourth Quarter and Fiscal Year 2021 Financial Outlook
The Company expects full-year 2021 constant-currency sales
growth in the range of 15% to 16%. Currency translation is expected
to increase full-year sales growth by approximately one percentage
point. The Company expects full-year 2021 non-GAAP EPS in the range
of $10.94 to $11.04. Please refer to the tables below for a
reconciliation of the projected GAAP to non-GAAP financial outlook
for the full-year.
The Company expects fourth quarter 2021 constant-currency sales
growth in the range of 5% to 7%. Currency translation is expected
to decrease fourth quarter sales growth by approximately two
percentage points. The Company expects fourth quarter 2021 non-GAAP
EPS in the range of $3.40 to $3.50. Please refer to the tables
below for a reconciliation of the projected GAAP to non-GAAP
financial outlook for the fourth quarter.
Conference Call
Waters Corporation will webcast its third quarter 2021 financial
results conference call today, November 2, 2021 at 8:00 a.m.
Eastern Time. To listen to the call and see the accompanying slide
presentation, please visit www.waters.com, select “Investors” under
the “About Waters” section, navigate to “Events &
Presentations,” and click on the “Webcast.” A replay will be
available through November 9, 2021 at midnight Eastern Time on the
same website by webcast and also by phone at (888) 566-0450.
About Waters Corporation
Waters Corporation (NYSE: WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass
spectrometry and thermal analysis innovations serving the life,
materials and food sciences for more than 60 years. With more than
7,400 employees worldwide, Waters operates directly in 35
countries, including 14 manufacturing facilities, and with products
available in more than 100 countries. For more information, visit
www.waters.com.
Non-GAAP Financial Measures
This press release contains financial measures, such as
constant-currency growth rate, adjusted operating income, adjusted
net income, adjusted earnings per diluted share and adjusted free
cash flow, among others, which are considered “non-GAAP” financial
measures under applicable U.S. Securities and Exchange Commission
rules and regulations. These non-GAAP financial measures should be
considered supplemental to, and not a substitute for, financial
information prepared in accordance with U.S. generally accepted
accounting principles (GAAP). The Company’s definitions of these
non-GAAP measures may differ from similarly titled measures used by
others. The non-GAAP financial measures used in this press release
adjust for specified items that can be highly variable or difficult
to predict. The Company generally uses these non-GAAP financial
measures to facilitate management’s financial and operational
decision-making, including evaluation of the Company’s historical
operating results, comparison to competitors’ operating results and
determination of management incentive compensation. These non-GAAP
financial measures reflect an additional way of viewing aspects of
the Company’s operations that, when viewed with GAAP results and
the reconciliations to corresponding GAAP financial measures, may
provide a more complete understanding of factors and trends
affecting the Company’s business. Because non-GAAP financial
measures exclude the effect of items that will increase or decrease
the Company’s reported results of operations, management strongly
encourages investors to review the Company’s consolidated financial
statements and publicly filed reports in their entirety.
Reconciliations of the non-GAAP financial measures to the most
directly comparable GAAP financial measures are included in the
tables accompanying this release.
Cautionary Statement
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements that
are not statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words “feels”,
“believes”, “anticipates”, “plans”, “expects”, “intends”,
“suggests”, “appears”, “estimates”, “projects” and similar
expressions, whether in the negative or affirmative, are intended
to identify forward-looking statements. The Company’s actual future
results may differ significantly from the results discussed in the
forward-looking statements within this release for a variety of
reasons, including and without limitation, risks related to the
effects of the ongoing COVID-19 pandemic on our business, financial
condition, results of operations and prospects, including: portions
of our global workforce being unable to work fully and/or
effectively due to working remotely, illness, quarantines,
government actions, facility closures or other reasons related to
the pandemic, increased risks of cyber-attacks resulting from our
temporary remote working model, disruptions in our manufacturing
capabilities or to our supply chain and distribution network,
volatility and uncertainty in global capital markets limiting our
ability to access capital, customers being unable to make timely
payments for purchases and volatility in demand for our products;
foreign exchange rate fluctuations potentially affecting
translation of the Company’s future non-U.S. operating results; the
impact on demand for the Company’s products, including delays or
disruptions to our distribution network, among the Company’s
various market sectors or geographies from economic, sovereign and
political uncertainties, particularly regarding the effect of new
or proposed tariff or trade regulations or changes in the
interpretation or enforcement of existing regulations; the effect
on the Company’s financial results from the United Kingdom exiting
the European Union; fluctuations in expenditures by the Company’s
customers, in particular large pharmaceutical companies;
introduction of competing products by other companies and loss of
market share; pressures on prices from competitors and/or
customers; regulatory, economic and competitive obstacles to new
product introductions; other changes in demand for the Company’s
products from the effect of mergers and acquisitions by the
Company’s customers; increased regulatory burdens as the Company’s
business evolves, especially with respect to the U.S. Food and Drug
Administration and U.S. Environmental Protection Agency, among
others; shifts in taxable income in jurisdictions with different
effective tax rates; the outcome of tax examinations or changes in
respective country legislation affecting the Company’s effective
tax rate; the effect of the adoption of new accounting standards;
the ability to access capital, maintain liquidity and service the
Company’s debt in volatile market conditions, including any
potential impact on the Company’s operations stemming from
sustained inflation, particularly in the U.S., as a large portion
of the Company’s cash is held and operating cash flows are
generated outside the U.S.; environmental and logistical obstacles
affecting the distribution of products and risks associated with
lawsuits and other legal actions, particularly involving claims for
infringement of patents and other intellectual property rights.
Such factors and others are discussed more fully in the sections
entitled “Forward-Looking Statements” and “Risk Factors” of the
Company’s annual report on Form 10-K for the year ended December
31, 2020, as well as in the sections entitled “Special Note
Regarding Forward-Looking Statements” and “Risk Factors” of the
Company’s quarterly reports on Form 10-Q for the quarterly periods
ended April 3, 2021, July 3, 2021, and October 2, 2021, each as
filed with the Securities and Exchange Commission (“SEC”), which
discussions are incorporated by reference in this release, as
updated by the Company’s future filings with the SEC. The
forward-looking statements included in this release represent the
Company’s estimates or views as of the date of this release and
should not be relied upon as representing the Company’s estimates
or views as of any date subsequent to the date of this release.
Except as required by law, the Company does not assume any
obligation to update any forward-looking statements.
Waters Corporation and Subsidiaries Consolidated
Statements of Operations (In thousands, except per share
data) (Unaudited) Three Months
Ended Nine Months Ended October 2, 2021
September 26, 2020 October 2, 2021 September 26,
2020 Net sales
$
659,233
$
593,784
$
1,949,425
$
1,578,707
Costs and operating expenses: Cost of sales
271,128
262,342
805,529
686,120
Selling and administrative expenses
152,545
135,430
453,954
400,614
Research and development expenses
41,986
34,971
125,027
101,115
Purchased intangibles amortization
1,759
2,657
5,408
7,900
Litigation provision
-
-
-
1,180
Operating income
191,815
158,384
559,507
381,778
Other income (expense), net (a)
(607
)
(1,039
)
18,073
(2,149
)
Interest expense, net
(8,533
)
(6,908
)
(23,707
)
(25,966
)
Income from operations before income taxes
182,675
150,437
553,873
353,663
Provision for income taxes
21,490
23,668
77,269
50,403
Net income
$
161,185
$
126,769
$
476,604
$
303,260
Net income per basic common share
$
2.63
$
2.04
$
7.72
$
4.89
Weighted-average number of basic common shares
61,359
62,002
61,771
62,057
Net income per diluted common share
$
2.60
$
2.03
$
7.66
$
4.86
Weighted-average number of diluted common shares and
equivalents
61,888
62,303
62,244
62,371
(a) During the nine months ended October 2, 2021, the
Company executed a settlement agreement to resolve patent
infringement litigation with Bruker Corporation and Bruker
Daltronik GmbH regarding their timsTOF product line. In connection
with the settlement, the Company is entitled to receive $10 million
in guaranteed payments, including minimum royalty payments, which
was recognized within Other income (expense), net in our
consolidated statement of operations. During the nine months ended
October 2, 2021, the Company recorded an unrealized gain of $10
million due to an observable change in the fair value of an
existing investment the Company does not have the ability to
exercise significant influence over.
Waters Corporation
and Subsidiaries Reconciliation of GAAP to Adjusted
Non-GAAP Net Sales by Operating Segments, Products &
Services, Geography and Markets Three Months Ended October
2, 2021 and September 26, 2020 (In thousands)
Current Period Constant Three Months
Ended Percent Currency Currency October
2, 2021 September 26, 2020 Change Impact
Growth Rate (a) NET SALES - OPERATING SEGMENTS
Waters $
581,811
$
533,466
9%
$
1,927
9%
TA
77,422
60,318
28%
956
27%
Total $
659,233
$
593,784
11%
$
2,883
11%
NET SALES - PRODUCTS & SERVICES
Instruments $
296,088
$
268,064
10%
$
759
10%
Service
240,100
217,545
10%
994
10%
Chemistry
123,045
108,175
14%
1,130
13%
Total Recurring
363,145
325,720
11%
2,124
11%
Total $
659,233
$
593,784
11%
$
2,883
11%
NET SALES - GEOGRAPHY Asia $
254,602
$
236,182
8%
$
38
8%
Americas
231,001
199,447
16%
595
16%
Europe
173,630
158,155
10%
2,250
8%
Total $
659,233
$
593,784
11%
$
2,883
11%
NET SALES - MARKETS Pharmaceutical $
398,338
$
343,001
16%
$
248
16%
Industrial
196,032
179,128
9%
1,606
9%
Academic & Government
64,863
71,655
(9%)
1,029
(11%)
Total $
659,233
$
593,784
11%
$
2,883
11%
NET SALES - EXCLUDING CHINA Total Net Sales $
659,233
$
593,784
11%
$
2,883
11%
China Net Sales
115,886
115,666
0%
3,604
(3%)
Total Net Sales Excluding China $
543,347
$
478,118
14%
$
(721)
14%
(a) The Company believes that referring to
comparable constant-currency growth rates is a useful way to
evaluate the underlying performance of Waters Corporation's net
sales. Constant-currency growth rate, a non-GAAP financial measure,
measures the change in net sales between current and prior year
periods, ignoring the impact of foreign currency exchange rates
during the current period. See description of non-GAAP financial
measures contained in this release.
Waters Corporation and Subsidiaries Reconciliation
of GAAP to Adjusted Non-GAAP Net Sales by Operating
Segments, Products & Services, Geography and Markets
Nine Months Ended October 2, 2021 and September 26, 2020
(In thousands) Current Period Constant
Nine Months Ended Percent Currency
Currency October 2, 2021 September 26, 2020
Change Impact Growth Rate (a) NET SALES
- OPERATING SEGMENTS Waters $
1,731,013
$
1,413,386
22%
$
37,147
20%
TA
218,412
165,321
32%
5,213
29%
Total $
1,949,425
$
1,578,707
23%
$
42,360
21%
NET SALES - PRODUCTS & SERVICES
Instruments $
873,632
$
664,817
31%
$
13,663
29%
Service
707,315
613,365
15%
18,628
12%
Chemistry
368,478
300,525
23%
10,069
19%
Total Recurring
1,075,793
913,890
18%
28,697
15%
Total $
1,949,425
$
1,578,707
23%
$
42,360
21%
NET SALES - GEOGRAPHY Asia $
754,091
$
603,471
25%
$
8,081
24%
Americas
653,252
546,405
20%
2,071
19%
Europe
542,082
428,831
26%
32,208
19%
Total $
1,949,425
$
1,578,707
23%
$
42,360
21%
NET SALES - MARKETS Pharmaceutical $
1,175,191
$
926,582
27%
$
22,610
24%
Industrial
581,884
474,592
23%
14,870
19%
Academic & Government
192,350
177,533
8%
4,880
6%
Total $
1,949,425
$
1,578,707
23%
$
42,360
21%
NET SALES - EXCLUDING CHINA Total Net Sales $
1,949,425
$
1,578,707
23%
$
42,360
21%
China Net Sales
346,030
252,713
37%
11,699
32%
Total Net Sales Excluding China $
1,603,395
$
1,325,994
21%
$
30,661
19%
(a) The Company believes that referring to
comparable constant-currency growth rates is a useful way to
evaluate the underlying performance of Waters Corporation's net
sales. Constant-currency growth rate, a non-GAAP financial measure,
measures the change in net sales between current and prior year
periods, ignoring the impact of foreign currency exchange rates
during the current period. See description of non-GAAP financial
measures contained in this release.
Waters Corporation
and Subsidiaries Reconciliation of GAAP to Adjusted Non-GAAP
Financials Three and Nine Months Ended October 2, 2021 and
September 26, 2020 (In thousands, except per share data)
Income from Operations Selling &
Operating Other before Provision for
Diluted Administrative Operating Income
Income Income Income Net
Earnings Expenses(a) Income Percentage
(Expense) Taxes Taxes Income per
Share Three Months Ended October 2, 2021
GAAP
$
154,304
$
191,815
29.1%
$
(607)
$
182,675
$
21,490
$
161,185
$
2.60
Adjustments:
Purchased intangibles amortization (b)
(1,759)
1,759
0.3%
-
1,759
400
1,359
0.02
Restructuring costs and certain other items (c)
(2,185)
2,185
0.3%
(403)
1,782
407
1,375
0.02
Certain income tax items (d)
-
-
-
-
-
(544)
544
0.01
Adjusted Non-GAAP
$
150,360
$
195,759
29.7%
$
(1,010)
$
186,216
$
21,753
$
164,463
$
2.66
Three Months Ended September 26, 2020
GAAP
$
138,087
$
158,384
26.7%
$
(1,039)
$
150,437
$
23,668
$
126,769
$
2.03
Adjustments:
Purchased intangibles amortization (b)
(2,657)
2,657
0.4%
-
2,657
524
2,133
0.03
Restructuring costs and certain other items (c)
(6,771)
6,771
1.1%
-
6,771
1,692
5,079
0.08
Certain income tax items (d)
-
-
-
-
-
(685)
685
0.01
Adjusted Non-GAAP
$
128,659
$
167,812
28.3%
$
(1,039)
$
159,865
$
25,199
$
134,666
$
2.16
Nine Months Ended October 2, 2021
GAAP
$
459,362
$
559,507
28.7%
$
18,073
$
553,873
$
77,269
$
476,604
$
7.66
Adjustments:
Purchased intangibles amortization (b)
(5,408)
5,408
0.3%
-
5,408
1,225
4,183
0.07
Restructuring costs and certain other items (c)
(3,669)
3,669
0.2%
(10,110)
(6,441)
(1,669)
(4,772)
(0.08)
Litigation settlement (e)
-
-
-
(10,083)
(10,083)
(1,916)
(8,167)
(0.13)
Certain income tax items (d)
-
-
-
-
-
(1,688)
1,688
0.03
Adjusted Non-GAAP
$
450,285
$
568,584
29.2%
$
(2,120)
$
542,757
$
73,221
$
469,536
$
7.54
Nine Months Ended September 26, 2020
GAAP
$
409,694
$
381,778
24.2%
$
(2,149)
$
353,663
$
50,403
$
303,260
$
4.86
Adjustments:
Purchased intangibles amortization (b)
(7,900)
7,900
0.5%
-
7,900
1,561
6,339
0.10
Restructuring costs and certain other items (c)
(33,054)
33,054
2.1%
(461)
32,593
7,373
25,220
0.40
Litigation provision (e)
(1,180)
1,180
0.1%
-
1,180
283
897
0.01
Certain income tax items (d)
-
-
-
-
-
(1,567)
1,567
0.03
Adjusted Non-GAAP
$
367,560
$
423,912
26.9%
$
(2,610)
$
395,336
$
58,053
$
337,283
$
5.41
(a) Selling & administrative expenses include
purchased intangibles amortization, litigation provisions and
settlements and asset impairments. (b) The purchased intangibles
amortization, a non-cash expense, was excluded to be consistent
with how management evaluates the performance of its core business
against historical operating results and the operating results of
competitors over periods of time. (c) Restructuring costs, mergers
and acquisition costs and certain other items were excluded as the
Company believes that the cost to consolidate operations, reduce
overhead, acquire companies and certain other income or expense
items are not normal and do not represent future ongoing business
expenses of a specific function or geographic location of the
Company. (d) Certain income tax items were excluded as these
non-cash expenses and benefits represent updates in management's
assessment of ongoing examinations or other tax items that are not
indicative of the Company’s normal or future income tax expense.
(e) Litigation settlement gains and provisions were excluded as
these items are isolated, unpredictable and not expected to recur
regularly.
Waters Corporation and Subsidiaries
Preliminary Condensed Unclassified Consolidated Balance
Sheets (In thousands and unaudited)
October 2, 2021 December 31, 2020 Cash, cash
equivalents and investments
$ 655,192
$ 443,146
Accounts receivable
532,957
573,316
Inventories
388,756
304,281
Property, plant and equipment, net
530,061
494,003
Intangible assets, net
246,080
258,645
Goodwill
436,754
444,362
Other assets
326,115
322,167
Total assets
$ 3,115,915
$ 2,839,920
Notes payable and debt
$ 1,613,618
$ 1,356,515
Other liabilities
1,207,075
1,251,261
Total liabilities
2,820,693
2,607,776
Total stockholders' equity
295,222
232,144
Total liabilities and stockholders' equity
$ 3,115,915
$ 2,839,920
Waters Corporation and Subsidiaries Preliminary Condensed
Consolidated Statements of Cash Flows Three and Nine Months
Ended October 2, 2021 and September 26, 2020 (In thousands
and unaudited) Three Months Ended Nine Months
Ended October 2, 2021 September 26, 2020
October 2, 2021 September 26, 2020 Cash flows
from operating activities: Net income
$ 161,185
$ 126,769
$ 476,604
$ 303,260
Adjustments to reconcile net income to net cash provided by
operating activities: Stock-based compensation
6,353
9,593
21,949
27,715
Depreciation and amortization
33,183
30,888
97,926
91,091
Change in operating assets and liabilities, net
(32,829)
5,329
(67,143)
100,959
Net cash provided by operating activities
167,892
172,579
529,336
523,025
Cash flows from investing activities: Additions to property,
plant, equipment and software capitalization
(39,725)
(28,311)
(116,614)
(125,340)
Business acquisitions, net of cash acquired
-
-
-
(76,664)
Investment in unaffiliated companies
(867)
(500)
(867)
(3,850)
Payments for intellectual property licenses
-
-
(7,000)
-
Net change in investments
73,270
(5,415)
(123,947)
(20,707)
Net cash provided by (used) in investing activities
32,678
(34,226)
(248,428)
(226,561)
Cash flows from financing activities: Net change in debt
5,100
(125,000)
251,463
(110,366)
Proceeds from stock plans
9,964
13,682
55,000
28,421
Purchases of treasury shares
(151,188)
(56)
(492,695)
(196,353)
Other cash flow from financing activities, net
408
2,772
2,325
10,330
Net cash used in financing activities
(135,716)
(108,602)
(183,907)
(267,968)
Effect of exchange rate changes on cash and cash equivalents
(208)
6,147
(8,994)
10,723
Increase in cash and cash equivalents
64,646
35,898
88,007
39,219
Cash and cash equivalents at beginning of period
460,056
339,036
436,695
335,715
Cash and cash equivalents at end of period
$ 524,702
$ 374,934
$ 524,702
$ 374,934
Reconciliation of GAAP Cash Flows from Operating
Activities to Free Cash Flow (a) Net cash
provided by operating activities - GAAP
$ 167,892
$ 172,579
$ 529,336
$ 523,025
Adjustments: Additions to property, plant, equipment and
software capitalization
(39,725)
(28,311)
(116,614)
(125,340)
Tax reform payments
-
38,454
38,454
38,454
Litigation settlement received
-
-
(3,367)
-
Major facility renovations
11,893
7,253
40,178
50,320
Free Cash Flow - Adjusted Non-GAAP
$ 140,060
$ 189,975
$ 487,987
$ 486,459
(a) The Company defines free cash flow as net cash flow from
operations accounted for under GAAP less capital expenditures and
software capitalizations plus or minus any unusual and non
recurring items. Free cash flow is not a GAAP measurement and may
not be comparable to free cash flow reported by other companies.
Waters Corporation and Subsidiaries Reconciliation
of Projected GAAP to Adjusted Non-GAAP Financial Outlook
Three Months Ended Twelve Months Ended
December 31, 2021 December 31, 2021 Range
Range Projected Sales Projected
constant-currency sales growth rate (a)
5
%
-
7
%
15
%
-
16
%
Projected currency impact
(2
%)
-
(2
%)
1
%
-
1
%
Projected sales growth rate as reported
3
%
-
5
%
16
%
-
17
%
Projected Earnings Per Diluted Share
Range
Range
Projected GAAP earnings per diluted share
$
3.37
-
$
3.47
$
11.02
-
$
11.12
Adjustments:
Purchased intangibles amortization
$
0.02
-
$
0.02
$
0.09
-
$
0.09
Restructuring costs and certain other items
$
-
-
$
-
$
(0.08
)
-
$
(0.08
)
Litigation settlement
$
-
-
$
-
$
(0.13
)
-
$
(0.13
)
Certain income tax items
$
0.01
-
$
0.01
$
0.04
-
$
0.04
Projected adjusted non-GAAP earnings per diluted share
$
3.40
-
$
3.50
$
10.94
-
$
11.04
(a) Constant-currency growth rates are a non-GAAP financial
measure that measures the change in net sales between current and
prior year periods, ignoring the impact of foreign currency
exchange rates during the current period. These amounts are
estimated at the current foreign currency exchange rates and based
on the forecasted geographical sales in local currency, as well as
an assessment of market conditions as of today, and may differ
significantly from actual results. These forward-looking
adjustment estimates do not reflect future gains and charges that
are inherently difficult to predict and estimate due to their
unknown timing, effect and/or significance.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102005188/en/
John Lynch, Vice President, Treasurer – (508) 482-2314 Caspar
Tudor, Manager, Investor Relations – (508) 482-2429
Waters (NYSE:WAT)
Historical Stock Chart
From Apr 2024 to May 2024
Waters (NYSE:WAT)
Historical Stock Chart
From May 2023 to May 2024